MAP2K7 and non-small cell lung carcinoma: To further explore the effect of combined targeted therapy and immune checkpoint inhibitors on cytokine production, we also evaluated the expression levels of several cytokines produced by NSCLC patients’ derived PBMCs before and after treatment in vitro with the PD-L1 inhibitor, atezolizumab, and the MEK inhibitor, selumetinib.